Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 7/20 | 0.63 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824056 | 0.81 | DAO (0.41) | DAOMEN1MAPTKMT2AGSK3B | |
| SCHEMBL20892550 | 0.80 | MRGPRX4 (0.43) | DAOALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL30844757 | 0.78 | GSK3B (0.67) | DAOALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL899479 | 0.77 | GSK3B (0.61) | DAOGPR35ALDH1A1KDM4EMEN1 | |
| SCHEMBL788050 | 0.77 | DAO (1.00) | DAOGPR35ALDH1A1KDM4EMEN1 | |
| SCHEMBL27843493 | 0.76 | GSK3B (0.49) | DAOALDH1A1MEN1KMT2AGSK3B | |
| SCHEMBL18701713 | 0.76 | DAO (0.65) | DAOGPR35ALDH1A1KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL8935127 | 0.76 | DAO (0.95) | DAOGPR35ALDH1A1KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL8935203 | 0.76 | GSK3B (0.59) | DAOGPR35ALDH1A1KDM4EMEN1 | |
| Bromide SCHEMBL8935164 | 0.76 | GSK3B (0.59) | DAOGPR35ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024131942-A1 | CYCLOPROPANE TLR7 AND TLR8 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2024-06-27 | — | — | WO | disclosed |
| CN-118239959-A | Cyclopropane TLR7 and 8 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-3466946-B1 | THIOPHENE, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL APPLICATION OF SAME | DONGBAO PURPLE STAR HANGZHOU BIOPHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-20220356174-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme, Inc. (US) | 2022-11-10 | — | — | US | disclosed |
| EP-3826999-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme Inc (US) | 2021-06-02 | — | — | EP | disclosed |
| WO-2021083182-A1 | URICOSURIC AGENT, SYNTHETIC METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 南京明德新药研发有限公司 | 2021-05-06 | — | — | WO | disclosed |
| CN-112739690-A | Pyridin-2-one compounds as SMARCA2 antagonists | 埃皮兹姆公司 | 2021-04-30 | — | — | CN | disclosed |
| WO-2020023657-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020023657-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20170135994-A9 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2017-05-18 | — | — | US | disclosed |
| WO-2013170112-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130231378-A1 | INHIBITORS OF AkT ACTIVITY | GLAXOSMITHKLINE LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-8410158-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8273782-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110071182-A1 | Inhibitors of AKT Activity | SMITHKLINE BEECHAM CORPORATION | 2011-03-24 | — | — | US | disclosed |
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| CN-101646427-A | Inhibitors of akt activity | SMITHKLINE BEECHAM CORP US | 2010-02-10 | — | — | CN | disclosed |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| WO-2007076423-A2 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356174-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | SMARCC1, SMARCC2, SMARCE1 | DAO 4390/4885GPR35 3297/4885ALDH1A1 1947/4885 |
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | DAO 2507/4885GPR35 2180/4885ALDH1A1 3652/4885 |
| US-20130231378-A1 | INHIBITORS OF AkT ACTIVITY | AKT2, AKT1, AKT3 | DAO 2507/4885GPR35 2180/4885ALDH1A1 3652/4885 |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, AKT3 | DAO 2507/4885GPR35 2180/4885ALDH1A1 3652/4885 |
| US-20110071182-A1 | Inhibitors of AKT Activity | AKT2, AKT1, AKT3 | DAO 2507/4885GPR35 2180/4885ALDH1A1 3652/4885 |
| US-20170135994-A9 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | DAO 3057/4885GPR35 2989/4885ALDH1A1 1573/4885 |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | DAO 2507/4885GPR35 2180/4885ALDH1A1 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.